Volume 52, Issue 5, Pages (November 2007)

Slides:



Advertisements
Similar presentations
Volume 62, Issue 4, Pages (October 2012)
Advertisements

Early Detection of Prostate Cancer in 2007
Volume 56, Issue 5, Pages (November 2009)
Volume 55, Issue 1, Pages 1-8 (January 2009)
Volume 72, Issue 1, Pages (July 2017)
Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit  Pim J. van Leeuwen, David Connolly, Anna.
The PSA Era is not Over for Prostate Cancer
Volume 54, Issue 2, Pages (August 2008)
Volume 68, Issue 2, Pages (August 2015)
Volume 57, Issue 1, Pages (January 2010)
Volume 50, Issue 1, Pages (July 2006)
Volume 52, Issue 1, Pages (July 2007)
Volume 51, Issue 2, Pages (February 2007)
Volume 62, Issue 5, Pages (November 2012)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 59, Issue 1, Pages (January 2011)
Testosterone Therapy in Men With Prostate Cancer
Volume 56, Issue 6, Pages (December 2009)
Volume 53, Issue 4, Pages (April 2008)
Volume 64, Issue 6, Pages (December 2013)
Volume 60, Issue 1, Pages (July 2011)
Volume 61, Issue 5, Pages (May 2012)
Volume 68, Issue 5, Pages (November 2015)
Volume 73, Issue 6, Pages (June 2018)
Volume 53, Issue 5, Pages (May 2008)
Volume 61, Issue 2, Pages (February 2012)
Prostate Cancer Epidemic in Sight?
Volume 61, Issue 3, Pages (March 2012)
Volume 63, Issue 4, Pages (April 2013)
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Volume 54, Issue 4, Pages (October 2008)
Elizabeth K. Bancroft, Rosalind A. Eeles
Volume 60, Issue 5, Pages (November 2011)
Towards Early and More Specific Diagnosis of Prostate Cancer
Prostate Cancer Detection: A View of the Future
Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance  Adam B. Weiner, Ruth Etzioni, Scott E. Eggener 
Volume 54, Issue 5, Pages (November 2008)
Volume 56, Issue 2, Pages (August 2009)
Volume 63, Issue 6, Pages (June 2013)
Volume 66, Issue 6, Pages (December 2014)
Prostate Cancer Epidemic in Sight?
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 53, Issue 4, Pages (April 2008)
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Volume 65, Issue 6, Pages (June 2014)
Volume 68, Issue 4, Pages (October 2015)
Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels
Volume 62, Issue 6, Pages (December 2012)
Volume 48, Issue 6, Pages (December 2005)
Volume 64, Issue 4, Pages (October 2013)
Volume 50, Issue 5, Pages (November 2006)
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Volume 53, Issue 1, Pages (January 2008)
The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.
Volume 59, Issue 4, Pages (April 2011)
Volume 72, Issue 1, Pages (July 2017)
European Urology is “Your” Journal
Thomas Steuber, Matthew Frank O'Brien, Hans Lilja  European Urology 
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
Apoorva R. Vashi, M.D., Joseph E. Oesterling, M.D. 
Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.
Volume 54, Issue 5, Pages (November 2008)
The Comparability of Models for Predicting the Risk of a Positive Prostate Biopsy with Prostate-Specific Antigen Alone: A Systematic Review  Fritz Schröder,
Volume 52, Issue 6, Pages (December 2007)
Volume 68, Issue 2, Pages (August 2015)
Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson 
Volume 53, Issue 2, Pages (February 2008)
Volume 51, Issue 2, Pages (February 2007)
Volume 54, Issue 3, Pages (September 2008)
Volume 51, Issue 5, Pages (May 2007)
Presentation transcript:

Volume 52, Issue 5, Pages 1358-1364 (November 2007) hK2 and Free PSA, a Prognostic Combination in Predicting Minimal Prostate Cancer in Screen-Detected Men within the PSA Range 4–10 ng/ml  René Raaijmakers, Stijn H. de Vries, Bert G. Blijenberg, Mark F. Wildhagen, Renske Postma, Chris H. Bangma, Claude Darte, Fritz H. Schröder  European Urology  Volume 52, Issue 5, Pages 1358-1364 (November 2007) DOI: 10.1016/j.eururo.2007.04.037 Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 1 ROC analyses for hK2, %fPSA,and the algorithm hK2/%fPSA in predicting minimal pCA. ROC=receiver operator characteristic; hK2=human glandular kallikrein 2; fPSA=free prostate-specific antigen; pCA=prostate cancer. European Urology 2007 52, 1358-1364DOI: (10.1016/j.eururo.2007.04.037) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 2 ROC analyses for the algorithms hK2/%fPSA and hK2/fPSA in predicting minimal pCA. ROC=receiver operating characteristic; hK2=human glandular kallikrein 2; fPSA=free prostate-specific antigen; pCA=prostate cancer. European Urology 2007 52, 1358-1364DOI: (10.1016/j.eururo.2007.04.037) Copyright © 2007 European Association of Urology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.